title: Biomarkers for Allergen Immunotherapy: A "Panoromic" View.
abstract: Biomarkers (BMKs) are biological parameters that can be measured to predict or monitor disease severity or treatment efficacy. The induction of regulatory dendritic cells (DCs) concomitantly with a downregulation of proallergic DC2s (ie, DCs supporting the differentiation of T-helper lymphocyte type 2 cells) in the blood of patients allergic to grass pollen has been correlated with the early onset of allergen immunotherapy efficacy. The combined use of omics technologies to compare biological samples from clinical responders and nonresponders is being implemented in the context of nonhypothesis-driven approaches. Such comprehensive "panoromic" strategies help identify completely novel candidate BMKs, to be subsequently validated as companion diagnostics in large-scale clinical trials.
authors.affiliation: Research and Development, Stallergenes SA, 6 Rue Alexis de Tocqueville, Antony Cedex 92183, France. Electronic address: pmoingeon@stallergenes.com.
authors.forename: Philippe
authors.initials: P
authors.lastname: Moingeon
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000378:metabolism; D054316:Biomarkers, Pharmacological / Q000378:metabolism; D019295:Computational Biology; D003713:Dendritic Cells / Q000276:immunology*; D003888:Desensitization, Immunologic; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
chemical_list: D019138:Antibodies, Blocking; D054316:Biomarkers, Pharmacological
keywords: Allergen; Biomarker; Companion diagnostic; Efficacy; Immunotherapy; Precision medicine; Safety